Navegação
Perspectivas de mercado Analisador de estoque Calendário de Dividendos Calendário de eventos Classificação de ações Notícias de mercados
Experimente grátis

Enlivex Therapeutics

NASDAQ ENLV
$1.41 0.0000 0.0000%
Today share price
Israel
Sector: Information Technology Industry: Application Software
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Показатель: 16 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

26.22M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
25.64M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.62
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
18.60M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-47.78 %

Upcoming events Enlivex Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Enlivex Therapeutics

Stock analysis Enlivex Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.89 51.25
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
0.87 10.93
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-1.05 39.06
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.02 -0.34
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-98.07 10.03

Price change Enlivex Therapeutics per year

7.20$ 29.40$
Min Max

Summary analysis Enlivex Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Enlivex Therapeutics

Revenue and net income Enlivex Therapeutics

All parameters

Stock news Enlivex Therapeutics

All news
16 agosto 2021 в 22:44

Enlivex Therapeutics Shares Rise 23% After Permission to Start Phase IIb Trial

16 agosto 2021 в 16:29

Enlivex Therapeutics Gets Approval to Start Phase IIb Trial for Covid-19 Treatment

About company Enlivex Therapeutics

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.
Address:
14 Einstein Street, Ness Ziona, Israel, 7403618
Company name: Enlivex Therapeutics
Issuer ticker: ENLV
ISIN: IL0011319527
Country: Israel
Exchange: NASDAQ
Currency: $
IPO date: 1995-12-12
Sector: Information Technology
Industry: Application Software
Site: https://www.enlivex.com

On which stock exchange are Enlivex Therapeutics (ENLV) stocks traded?

Enlivex Therapeutics (ENLV) stocks are traded on NASDAQ.

What is the ticker of Enlivex Therapeutics stocks (ENLV)?

The stock ticker of Enlivex Therapeutics’s stocks or in other words, the code is ENLV. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Enlivex Therapeutics (ENLV) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Enlivex Therapeutics (ENLV) belongs to the «Information Technology» sector and the «Application Software» industry.

In what currency are Enlivex Therapeutics (ENLV) stocks traded?

Enlivex Therapeutics (ENLV) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Enlivex Therapeutics (ENLV) stocks today?

The current price of Enlivex Therapeutics stocks on 19.05.2024 is 1.41 dollars. per share.

What is the dynamics of Enlivex Therapeutics (ENLV) stocks from the beginning of the year?

Enlivex Therapeutics (ENLV) quotes have increased by -57.27% from the beginning of the year up to 1.41 dollars. per 1 stocks.

How much did Enlivex Therapeutics (ENLV) stocks increase in мае 2024?

This month Enlivex Therapeutics (ENLV) quotes have increased by -12.42% to 1.41 dollars. per share.

How much are Enlivex Therapeutics (ENLV) stocks worth?

Today, on October, 19.05.2024 Enlivex Therapeutics’s (ENLV) stocks cost 1.41 dollars..

What is the market capitalization of Enlivex Therapeutics (ENLV)?

Capitalization is the market value of Enlivex Therapeutics (ENLV) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 19.05.2024, the market capitalization of Enlivex Therapeutics (ENLV) is estimated at about 26223963 dollars.